payload-neuronal-calcium-sensor-modulation-therapy

📖 Wiki Page

general973 wordssynced 2026-04-02

Neuronal Calcium Sensor Modulation Therapy

Overview

flowchart TD ideas_payload_neuronal_calcium["payload-neuronal-calcium-sensor-modulation-thera"] ideas_payload_neuronal_calcium["approach"] ideas_payload_neuronal_calcium -->|"related to"| ideas_payload_neuronal_calcium style ideas_payload_neuronal_calcium fill:#81c784,stroke:#333,color:#000 ideas_payload_neuronal_calcium["targets"] ideas_payload_neuronal_calcium -->|"related to"| ideas_payload_neuronal_calcium style ideas_payload_neuronal_calcium fill:#81c784,stroke:#333,color:#000 ideas_payload_neuronal_calcium["family"] ideas_payload_neuronal_calcium -->|"related to"| ideas_payload_neuronal_calcium style ideas_payload_neuronal_calcium fill:#81c784,stroke:#333,color:#000 ideas_payload_neuronal_calcium["restore"] ideas_payload_neuronal_calcium -->|"related to"| ideas_payload_neuronal_calcium style ideas_payload_neuronal_calcium fill:#81c784,stroke:#333,color:#000 style ideas_payload_neuronal_calcium fill:#4fc3f7,stroke:#333,color:#000

This therapeutic approach targets the neuronal calcium sensor (NCS) protein family to restore calcium homeostasis disrupted in Alzheimer's disease (AD), Parkinson's disease (PD), and related neurodegenerative disorders. The NCS family includes calbindin-D28k, parvalbumin, calretinin, neuronal calcium sensor-1 (NCS1/frequenin), and visinin-like proteins (VILIPs). These proteins buffer intracellular calcium, regulate synaptic plasticity, and protect against excitotoxic cell death.

Mechanism of Action

...

Neuronal Calcium Sensor Modulation Therapy

Overview

Mermaid diagram (expand to render)

Mechanism of Action

Primary Target: NCS Protein Restoration and Modulation

The therapeutic strategy operates through multiple mechanisms:

1. Calcium Buffering Restoration

Calbindin and parvalbumin are EF-hand calcium-binding proteins that act as endogenous calcium buffers
In AD and PD brains, calbindin-expressing neurons are relatively spared, while parvalbumin neurons degenerate
Restoring or enhancing NCS expression protects against calcium-dependent excitotoxicity

2. Synaptic Protection via NCS1/Frequenin

NCS1 regulates voltage-gated calcium channels and synaptic vesicle trafficking
NCS1 overexpression protects against β-amyloid toxicity
Small molecule NCS1 modulators can enhance its neuroprotective function

3. VILIP-1 Pathological Signaling Blockade

VILIP-1 is elevated in AD cerebrospinal fluid and serves as a biomarker
VILIP-1 modulates calcium-dependent signaling in ways that may contribute to tau pathology
Antibodies or small molecules can block VILIP-1 pathological signaling

4. Calcium Homeostasis Network Restoration

Coordinate with calcium channel modulators (L-type, N-type, T-type)
Synergize with mitochondrial calcium uniporter (MCU) modulators
Combine with sodium-calcium exchanger (NCX) enhancers

10-Dimension Rubric Score: 76/100

| Dimension | Score | Rationale |
|----------|-------|----------|
| Novelty | 8 | Novel therapeutic approach targeting underappreciated calcium sensor family |
| Mechanistic Rationale | 9 | Strong biological rationale - NCS neurons are selectively spared in neurodegeneration |
| Root-Cause Coverage | 8 | Addresses calcium dysregulation, a core pathological mechanism |
| Delivery Feasibility | 7 | AAV-mediated gene delivery or small molecule approaches viable |
| Safety Plausibility | 7 | NCS proteins are endogenous - modulation has precedent |
| Combinability | 9 | Strong synergy with calcium channel modulators, anti-excitotoxicity approaches |
| Biomarker Availability | 8 | CSF calbindin, VILIP-1 levels enable patient stratification |
| De-risking Path | 7 | Calbindin-TdTomato mice enable proof-of-concept |
| Multi-disease Potential | 8 | AD, PD, ALS, HD all show calcium dysregulation |
| Patient Impact | 7 | Addresses fundamental neuronal vulnerability |

Disease Coverage

| Disease | Coverage | Priority |
|---------|----------|----------|
| AD | 9 | Primary - calbindin loss in vulnerable neurons |
| PD | 8 | Secondary - calcium dysregulation in dopaminergic neurons |
| ALS | 7 | Secondary - excitotoxicity contribution |
| FTD | 7 | Secondary - TDP-43 and calcium dysregulation |
| HD | 8 | Secondary - calbindin deficiency contributes |
| Aging | 8 | Preventive - calcium buffering decline |
| DLB | 7 | Concomitant - Lewy body and calcium interplay |
| CBS | 6 | Adjacent - tau and calcium interactions |
| PSP | 6 | Adjacent - 4R-tau and calcium dysregulation |

Therapeutic Approaches

Approach 1: Gene Therapy (AAV-Calbindin)

Deliver calbindin via AAV9 or AAV-PHP.eB
Target entorhinal cortex and hippocampus
Enable neuron-specific promoters (Synapsin, CamKIIa)
Advantages: Direct protein restoration
Risks: Overexpression could disrupt calcium signaling

Approach 2: Small Molecule NCS1 Modulators

Target NCS1 allosteric sites
Enhance NCS1 neuroprotective signaling
Develop high-throughput screening assays
Advantages: Oral bioavailability
Risks: Limited blood-brain barrier penetration

Approach 3: VILIP-1 Blocking Antibodies

Monoclonal antibodies against pathological VILIP-1
CSF or intrathecal delivery
Advantages: Precise pathological targeting
Risks: Immunogenicity, delivery challenges

Approach 4: Combination Calcium Restoration

NCS modulation + L-type calcium channel modulators + NCX enhancers
Comprehensive calcium homeostasis restoration
Advantages: Multi-target approach
Risks: Complexity of dosing

Implementation Roadmap

Phase 1: Preclinical Validation (Months 1-12)

Test calbindin overexpression in 5xFAD mice
Assess synaptic protection and memory improvement
Validate biomarker changes in CSF

Phase 2: IND-enabling Studies (Months 12-24)

GMP production of AAV-calbindin or small molecule
GLP toxicology in non-human primates
Biomarker validation in larger cohorts

Phase 3: Clinical Trials (Months 24-48)

Phase I safety in healthy volunteers (gene therapy) or AD patients
Phase II efficacy in early AD patients
Biomarker-driven patient enrichment

De-risking Path

Key Risk: Delivery to Correct Neurons

Mitigation: Use neuron-specific promoters
Validation: Calbindin-TdTomato reporter in mice

Key Risk: Calcium Signaling Disruption

Mitigation: Titrate expression levels carefully
Validation: Calcium imaging in patient-derived neurons

Key Risk: Off-target Effects

Mitigation: Selective NCS1 modulators vs. broad calcium channel blockers
Validation: Comprehensive electrophysiology

Biomarker Strategy

Patient Stratification:

Low CSF calbindin → enriched patient population
High CSF VILIP-1 → pathological signaling present

Pharmacodynamic Markers:

CSF calbindin levels post-treatment
Calcium imaging in patient-derived neurons
Synaptic markers (synaptophysin, PSD-95)

Cross-linking to NeuroWiki Pages

[Calcium dysregulation mechanisms](/mechanisms/calcium-dysregulation-4r-tauopathies)
[Calbindin gene](/genes/calb1)
[Parvalbumin gene](/genes/pvalb)
[Calcium homeostasis in AD](/mechanisms/calcium-ad-pathway)
[Excitotoxicity mechanisms](/diseases/als)

Competitive Landscape

Previous calcium channel blockers (nimodipine, memantine) had limited efficacy
NCS-targeted approach is more selective than broad calcium modulation
Gene therapy for calcium-binding proteins is novel

Actionable Next Steps

Literature review: Confirm NCS expression changes in AD/PD postmortem brain

Target validation: Test calbindin overexpression in iPSC-derived AD neurons

Biomarker discovery: Validate CSF NCS levels as patient stratification tool

Small molecule screening: Develop NCS1 modulators with blood-brain barrier penetration

IND-enabling studies: Begin regulatory discussions with FDA

References

[Marambaud et al., The calcium-sensing domain protects against Abeta neurotoxicity (2009)](https://pubmed.ncbi.nlm.nih.gov/18814954/)

[Choi et al., Subtype-specific calcium channel dysfunction in AD (2017)](https://pubmed.ncbi.nlm.nih.gov/29258959/)

[Mattson & Rychlik, Calcium and neuronal death (1993)](https://pubmed.ncbi.nlm.nih.gov/8404408/)

[Heizmann & Braun, Calcium binding proteins in neurodegeneration (2002)](https://pubmed.ncbi.nlm.nih.gov/12027156/)

[Moreno et al., Calbindin deficiency in HD (2016)](https://pubmed.ncbi.nlm.nih.gov/27222429/)

[Sullivan & Young-Pearse, NCS1 in synaptic function (2014)](https://pubmed.ncbi.nlm.nih.gov/24824288/)

[Bernstein et al., NCS1 modulation of calcium channels (2013)](https://pubmed.ncbi.nlm.nih.gov/24075980/)

📖 View canonical wiki page →